MariMed’s Record Quarter and Bold New York Plan

In today’s Trade To Black podcast presented by Flowhub, Shadd Dales and Anthony Varrell continue earnings season with MariMed (CSE: MRMD) CEO Jon Levine and Chief Commercial Officer Ryan Crandall, fresh off the company’s strongest quarter ever and with a bold new plan involving New York.

MariMed posted record Q3 revenue of $44.2 million, up 8.5% from a year ago, with retail up 8.4% and wholesale up 8.1%. Adjusted EBITDA was $4.7 million, up 18% from last quarter, and the company ended the quarter with $10.4 million in cash, its strongest position in two years. Gross margin held steady from Q2 at 40% but slipped 140 basis points from a year ago as wholesale prices fell. Levine says expenses are rising as MariMed invests ahead of growth, particularly in innovation and its New York launch.

The company’s branded products are now in 721 stores, up 13%, and its market share in core states rose 150 basis points. Betty’s Eddies remains the top edible in Massachusetts, where voters rejected the Question 8 repeal by 76%, and is now number two in Maine. Crandall credits constant innovation and consumer trust. At retail, transactions at MariMed’s Thrive stores rose 7% and loyalty membership is up 31% this year. Crandall says growing that loyalty program is a major focus heading into 2027. In Illinois, new rules let MariMed add medical sales at three more stores and open drive-through service, and the federal hemp restrictions are already lifting sales near the Tennessee border.

Crandall calls New York the largest state opportunity MariMed has seen. With no stores there, the company will enter through wholesale and licensing, with the potential to nearly double its door count. Levine expects upfront marketing costs in early 2027 while its processing facility is built out.

On consolidation, Levine says MariMed is always listening but won’t sell for the wrong number. Its acquisition focus has shifted to operating businesses that need help or restructuring rather than paper licenses. He notes that the company’s roughly $78 million in debt is mostly first mortgages at 55% to 60% of appraised property value, with some properties unencumbered. MariMed has approval for a reverse split and would pursue a U.S. exchange listing if rescheduling or banking reform arrives.

Is MariMed a buyer or a seller? Tune in to hear the full conversation.


You might also like

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More